Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial

Per-protocol efficacy analyses (n=151) found 53.4% of pts had a complete response within 3 months of first dose and response was maintained in 45.5% of pts at 12 months with nadofaragene firadenovec (adenovirus that delivers human interferon alfa-2b cDNA into bladder epithelium).

Source:

The Lancet Oncology